CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 3,005 enrolled
Drug / intervention
Lasmiditan 50 mg +3 moredrug
Likely dose
Lasmiditan 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02605174
NCT02605174Phase 3Completed
CompareCT.gov

A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)

Eli Lilly and Company·interventional·Posted Nov 16, 2015·Updated Sep 23, 2019

In Brief

A Phase 3 clinical trial evaluating Lasmiditan 50 mg, Lasmiditan 100 mg, and 2 other interventions for Migraine With or Without Aura. Completed, enrolled 3,005 participants across 95 sites.

Detailed Summary

This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine With or Without Aura
CountriesUnited States
CollaboratorsCoLucid Pharmaceuticals

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 16, 2015
Enrollment StartMay 1, 2016
Primary CompletionJun 30, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.6 years ago

Interventions

Lasmiditan 50 mgdrug

One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)

Lasmiditan 100 mgdrug

One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)

Lasmiditan 200 mgdrug

One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)

Placebodrug

Two placebo tablets to match lasmiditan doses.